Brazil's Omni raises fresh round to double medication-benefit coverage
What's the deal? Omni, a Brazilian employer-benefits startup that administers medication coverage, has closed a new funding round led by ACNext, with existing investors GreenRockDealroom has a profile for this one. Try Dealroom → and EnseadaDealroom has a profile for this one. Try Dealroom → participating. The company has now raised US$7.67M across three rounds since 2024.
What does Omni do? Founded in 2024 by Fernando Domingues, a co-founder of telemedicine company Conexa Saúde, Omni manages employer-funded medication benefits. Employers and health plan operators pay a monthly per-person fee, while employees use an app to get prescriptions approved and pay via an Omni Pix transfer. Its revenue comes from managing risk and preventing fraud, not from selling medication.
By the numbers: Omni serves more than 70 clients, including AzulDealroom has a profile for this one. Try Dealroom →, Light, and MetLifeDealroom has a profile for this one. Try Dealroom →, covering 350,000 lives. Annualised revenue stands at US$6.65M.
Who's backing it? Lead investor ACNext is a venture firm founded by former Accenture executives. GreenRock is backed by the founding families of the Salomão Zoppi laboratory, and Enseada is the family office of the Larragoiti family, founders of insurer SulAméricaDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Omni plans to use the capital to double its covered lives by the end of 2027. It projects reaching US$12.8M in revenue and breaking even by that point.
The signal: The round is a bet on an underdeveloped Brazilian niche. Medication coverage is not mandated by the health regulator, and Omni competes with established providers including Funcional, VidaLink, and Epharma — leaving room for a specialist built on fraud prevention and risk management to grow.
Read more: startupresearcher.com
Image credit: Generated with Gemini
